diabetes therapy articles & resources on Made-in-China.com

Insulin Pump Therapy for Diabetics Get Easier Due to Novo Nordisk and Roche Diabetes

Nov 26, 2013

Denmark-based Novo Nordisk has announced that the European Medicines Agency (EMA's) Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing of the NovoRapid PumpCart in Europe. NovoRapid PumpCart is a 1.6ml ...

Tags: Health, Medicine

Boehringer and Eli Lilly and Company Have Announced The Submission of New Drug Application

Mar 27, 2013

Boehringer Ingelheim and Eli Lilly and Company have announced the submission of new drug application (NDA) to FDA for an investigational type 2 diabetes mellitus (T2D) treatment, empagliflozin. Empagliflozin belongs to sodium glucose ...

Tags: diabetes therapy, drug application, drug

Novo Nordisk Has Received an Approval of The Price From Chuikyo

Feb 19, 2013

Novo Nordisk has received an approval of the price from Japan's Central Social Insurance Medical Council (Chuikyo), the advisory committee to the Minister of Health, Labour and Welfare, and is set to launch Tresiba (insulin degludec) in ...

Tags: diabetes therapy, Medical, Novo Nordisk

Labour and Welfare Has Cleared Novo Nordisk's Diabetes Therapy, Ryzodeg

Dec 27, 2012

The Japanese Ministry of Health, Labour and Welfare has cleared Novo Nordisk's diabetes therapy, Ryzodeg. Ryzodeg, which has been approved to be administered once or twice daily, is the global brand name for insulin degludec/insulin ...

Tags: Novo Nordisk, diabetes therapy, Japan, Health

Roche Announces US Launch of ACCU-CHEK Combo System, Designed for People

Dec 17, 2012

Roche has announced the US launch of ACCU-CHEK Combo system, designed for people with diabetes condition. The system, which combines a blood glucose meter with an insulin pump, utilizes Bluetooth technology for two-way wireless ...

Tags: diabetes therapy, clinical application, clinical technology

FDA Granted Orphan Drug Designation for Andromeda Biotech's DiaPep277 to T1D Patients

Dec 7, 2012

The FDA has granted orphan drug designation for Andromeda Biotech's DiaPep277 to treat type 1 diabetes (T1D) patients with residual beta cell function. The orphan drug status offers seven years marketing exclusivity from the time of ...

Tags: DiaPep277, type 1 diabetes, T1D, residual beta cell

The Filing Is Based on a Global Phase III Clinical Development Program

Dec 4, 2012

Janssen Research & Development has submitted a new drug application (NDA) to the FDA for canagliflozin to treat adult patients with type 2 diabetes. The filing is based on a global Phase III clinical development program, including nine ...

Tags: Janssen Research&Development, SGLT2, cardiovascular study

ViaCyte Has Received a $10.1m Strategic Partnership Award From CIRM

Nov 28, 2012

ViaCyte has received a $10.1m strategic partnership award from the California Institute for Regenerative Medicine (CIRM) to develop VC-01, which is a regenerative medicine, consisting of pancreatic beta cell progenitors in a durable ...

Tags: ViaCyte, Diabetes Therapy Development, CIRM

diabetes therapy

Related Products